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Abstract: Curcumin may exert a more selective cytotoxic effect in tumor cells with elevated 
levels of free radicals. Here, we investigated whether curcumin can modulate etoposide action 
in myeloid leukemia cells and in normal cells of hematopoietic origin. HL-60 cell line, normal 
myeloid progenitor cluster of differentiation (CD)-34+ cells, and granulocytes were incubated 
for 4 or 24 hours at different concentrations of curcumin and/or etoposide. Brown Norway 
rats with acute myeloid leukemia (BNML) were used to prove the influence of curcumin 
on etoposide action in vivo. Rats were treated with curcumin for 23 days and etoposide was 
administered for the final 3 days of the experiment. Curcumin synergistically potentiated the 
cytotoxic effect of etoposide, and it intensified apoptosis and phosphorylation of the histone 
H2AX induced by this cytostatic drug in leukemic HL-60 cells. In contrast, curcumin did not 
significantly modify etoposide-induced cytotoxicity and H2AX phosphorylation in normal 
CD34+ cells and granulocytes. Curcumin modified the cytotoxic action of etoposide in HL-60 
cells through intensification of free radical production because preincubation with N-acetyl-l-
cysteine (NAC) significantly reduced the cytotoxic effect of curcumin itself and a combination 
of two compounds. In contrast, NAC did not decrease the cytotoxic effect of etoposide. Thus, 
oxidative stress plays a greater role in the cytotoxic effect of curcumin than that of etoposide 
in HL-60 cells. In vitro results were confirmed in a BNML model. Pretreatment with curcumin 
enhanced the antileukemic activity of etoposide in BNML rats (1.57-fold tumor reduction 
versus etoposide alone; P,0.05) and induced apoptosis of BNML cells more efficiently than 
etoposide alone (1.54-fold change versus etoposide alone; P,0.05), but this treatment protected 
nonleukemic B-cells from apoptosis. Thus, curcumin can increase the antileukemic effect of 
etoposide through reactive oxygen species in sensitive myeloid leukemia cells, and it is harm-
less to normal human cells.
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Introduction
Curcumin is a phytochemical compound isolated from the rhizomes of Curcuma 
longa L. having antitumor activity.1 Curcumin might be selectively cytotoxic to tumor 
cells and is less cytotoxic to normal cells.2 Similarly, curcumin could selectively 
modulate the cytotoxic effect of many chemotherapeutic agents in tumor cells.3 Such 
selective action of curcumin results from differences in metabolism between normal 
and malignant cells. Cancer cells have many mutations in proto-oncogenes, which 
can contribute to an increase in free radicals.4 Curcumin can exert selective pro-
oxidant action in cancer cells with high levels of free radicals and, in this way, induce 
apoptosis.5,6 Curcumin may also inhibit the antiapoptotic genes that are often over-
expressed in leukemia cells, which may be a cause of resistance to anticancer drugs.7 
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Among antiapoptotic genes, special attention has recently 
been paid to survivin, which is overexpressed in acute myel-
oid leukemia (AML) stem/progenitor cells and is associated 
with poor prognosis.8,9
The effect of curcumin on the activity of certain cytostatic 
drugs, including etoposide, is not yet well known. Etoposide 
is used in the treatment of a wide spectrum of solid tumors, 
lymphomas, and leukemias.10 Several studies have shown 
that curcumin can inhibit the activation, nuclear transloca-
tion, and binding to DNA of nuclear factor-κB (NFκB) in 
cancer cells.11 In contrast, etoposide enhances the activity of 
this nuclear factor, promoting cell survival.12 It is believed 
that inhibition of NFκB could increase the cytotoxic effects 
of etoposide in cancer cells. Therefore, it can be supposed 
that curcumin will potentiate the effect of etoposide, inter 
alia, by inhibiting NFκB.
A topoactive drug, etoposide inhibits the topoisomerase 
II–DNA cleavable complex, resulting in DNA damage, 
including double-stranded DNA breaks (DSBs), causing 
chromosomal aberration or apoptosis.13,14 The myelotoxic 
and leukemogenic action of etoposide makes it difficult to 
use a sufficiently high dose of this medication. The reason 
for the strong cytotoxicity of etoposide in hematopoietic 
precursors is the high activity of not only topoisomerase II, 
but also myeloperoxidase (MPO).15 MPO metabolizes 
etoposide to highly toxic phenoxyl radicals and ortho-
quinones. These radicals lead to a decrease in glutathione 
(GSH) and enhancement of oxidative stress, which in turn 
contributes to an increase in DNA damage.16 Oxidative 
damage to phospholipids and the loss of mitochondrial 
membrane integrity result in cell apoptosis. MPO  activity 
dominates cytochrome P450 expression in myeloid 
lineage cells.17
Etoposide also exerts particularly strong mutagenic 
effects in precursors of myeloid lineage. It does not cause 
any other type of leukemia, but treatment-related acute 
myeloid leukemia (t-AML) occurs in a large percentage of 
patients treated with this cytostatic drug.18 The results of 
studies indicate a role of etoposide phenoxyl radicals in the 
development of t-AML. It has been proved that the presence 
of phenoxyl radicals of etoposide correlates with the appear-
ance of MLL gene translocation, characteristic of t-AML, in 
early myeloid precursors expressing cluster of differentiation 
(CD)-34 stem cell antigens.19
Compounds that could increase the cytotoxic effect of 
etoposide in cancer cells and, at the same time, not increase 
the side effects of etoposide in bone marrow cells are still 
being sought. One such compound possessing selective 
action in cancer cells is curcumin. So far, there has been no 
research on the effects of curcumin on the activity of etopo-
side in myeloid leukemia cells.
The aim of this study was to determine whether cotreatment 
with curcumin can modify the effect of etoposide in leukemic 
cells and their normal counterparts in vitro and in vivo.
Materials and methods
cell culture conditions
An HL-60 cell line was purchased from the European 
branch of American Type Culture Collection (ATCC, UK). 
The cells were cultured in Roswell Park Memorial Institute 
(RPMI)-1640 supplemented with 10% fetal bovine serum. 
Primary human cord blood CD34+ cells were purchased from 
Stemcell Technologies Inc (Vancouver, Canada). CD34+ cells 
were grown in  StemSpan™ serum-free expansion medium 
containing pretested bovine serum albumin, insulin, trans-
ferrin, and supplements in Iscove’s Modified Dulbecco’s 
Medium. The medium was supplemented with StemSpan 
expansion supplement CC100 containing recombinant human 
(rh) Fms-related tyrosine kinase 3 ligand, rh stem cell factor, rh 
interleukin (IL)-3, and rh IL-6. These cells were isolated from 
the umbilical cord blood mononuclear cells of healthy donors 
using positive immunomagnetic separation techniques. The 
purity of CD34+ cells .90% was checked via flow cytometry 
(Becton Dickinson [BD] Biosciences Immunocytometry Sys-
tems, San Jose, CA, USA). Immediately after thawing, a viable 
cell count was done using the trypan blue exclusion method. 
HL-60 cells and CD34+ cells were cultured without antibiotics 
at 37°C in a 5% CO
2
 and 95% humidified atmosphere. CD34+ 
cells were cultured for no longer than 2 weeks.
Cells were incubated with different concentrations of 
curcumin and/or etoposide dissolved in dimethyl sulfoxide 
(DMSO) for 4 or 24 hours. Control cells were treated only 
with DMSO, the concentration of which was 0.06% in the 
culture medium. In accordance with the guidelines of the 
Bioethics Committee of the Jagiellonian University, ethics 
approval is not required on cells commercially purchased in 
the company. Therefore, research on HL-60 cell line (ATCC, 
UK) and on CD34 cells (Stem Cell Technology, Canada) did 
not require ethics approval.
isolation of granulocytes from human 
venous/peripheral blood
Heparinized blood (lithium heparin – anticoagulant) was 
collected from healthy donors (female, 22–47 years of age) 
after approval was obtained from the Bioethics Committee 
of the Jagiellonian University and donors provided written 
informed consent. To isolate granulocytes, blood samples 
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curcumin enhances etoposide-induced antileukemic effect
The granulocytes were counted and their viability was 
assessed using 0.4% trypan blue exclusion methods. The 
homogeneity of the population was evaluated with flow 
cytometry technique. Detailed information on the isolation of 
granulocytes is provided in the Supplementary materials.
Determination of cytotoxicity, apoptosis, 
and combination index
To determine the cytotoxicity after treatment, HL-60 cells 
in the logarithmic growth phase, primary CD34+ cells, and 
granulocytes were seeded in 24-well culture plates at a 
density of 0.4×106 cells per well and were incubated for 
24 hours with different concentrations of etoposide and/or 
curcumin. After incubation, the cells were washed twice in 
phosphate-buffered saline (PBS) (230 × g centrifuged) for 
5 minutes. Cytotoxicity was determined using propidium 
iodide (PI) staining. Apoptosis was detected using annexin-
V-allophycocyanin and PI staining. The cells were immedi-
ately analyzed by flow cytometry. Analysis was performed 
on at least 20,000 single cells. Detailed information on the 
staining is provided in the Supplementary materials. Cal-
cuSyn (Biosoft, Cambridge, UK) software was used in the 
calculation of half-maximal inhibitory concentration (IC
50
) 
and the combination index (CI) for HL-60 cells. The CI was 
evaluated based on the multiple drug effect equation of Chou-
Talalay.20 CI values ,1 indicate synergism, =1 indicate an 
additive effect, and .1 indicate antagonism.
cell staining and analysis for h2aX, cell 
cycle, and nFκB
For the detection of DNA damage, mainly DSBs, phosphory-
lated histone H2AX (γ-H2AX) was detected as a marker.21,22 
The cells were fixed on ice with 1% methanol-free formal-
dehyde solution in PBS for 15 minutes and permeabilized 
with ice-cold 70% ethanol in deionized water. Cells (0.4×106) 
were stained with primary rabbit monoclonal anti-γ-H2AX 
(Ser139) antibody. Next, they were incubated with the sec-
ondary anti-rabbit immunoglobulin (Ig) G (H+L) F(ab′)
2
 
fragment of goat antibody conjugated with Alexa Fluor 647. 
DNA was stained with PI and RNase A in PBS.
To determine the level of nuclear NFκB in HL-60 cells, the 
cells were prepared using the Cycletest™ PLUS DNA reagent 




antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
The cells were analyzed with an LSR II flow cytometer, 
and quantitative analysis of γ-H2AX-positive cells or the 
nuclear level of NFκB was carried out using FACSDiva 
software (BD Biosciences Immunocytometry Systems).
The level of cellular NFκBp65 was also determined 
through Western blot analysis. Detailed information on 
the staining procedure is provided in the Supplementary 
materials.
Measurement of reactive oxygen species




DCFDA) staining. After incubation with 
the investigated compounds for 24 hours, the cells were 
washed with Hank’s balanced salt solution and incubated 
with 10 μM CM-H
2
DCFDA for 30 minutes in the dark. The 
intensity of fluorescence was measured in an LSR II flow 
cytometer. The analysis was performed on at least 20,000 
events. Detailed information on the staining procedure is 
provided in the Supplementary materials.
Determination of intracellular gsh in 
hl-60 cells
Total GSH in the HL-60 cells was measured spectrophoto-
metrically by the Ellman method23 based on the reaction of 
thiols with the chromogenic 5,5′-dithiobis-2-nitrobenzoate, 
whereby formation of the yellow dianion of 5-thio-2-
nitrobenzoic acid is measured. GSH concentrations were 
expressed as nanomoles per milligram of protein. Detailed 




The liquid chromatography (LC) separation was performed 
on an Agilent HPLC 1100 series system (Agilent, Waldbronn, 
Germany). The samples were separated on a Supelco 
Discovery C18 column (250 mm ×4.0 mm, 5 mm particle 
size). Mass spectrometry (MS) analyses were performed on 
an Applied Biosystems MDSciex (Concord, ON, Canada) 
API 2000 triple quadrupole mass spectrometer equipped with 
an electrospray ionization interface. Detailed information 
on the LC/MS analysis is provided in the Supplementary 
materials.
BnMl model of myeloid leukemia
All experiments were performed in accordance with 
legal requirements, under a license granted by the Jag-
iellonian University Ethical Committee. Male Brown 
Norway (BN/CrlCmd) rats were obtained from the Polish 
Academy of Sciences Medical Research Center (Warsaw, 
Poland). Brown Norway rat myeloid leukemia (BNML) 
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spleen-derived leukemia cells (1×106 cells in 0.5 mL of 
PBS injected into tail vein). Cells were kindly provided 
by Professor ACM Martens, Utrecht University, the 
Netherlands.24
The doses of curcumin (100 and 200 mg/kg) were chosen 
based on previous reports.2,25 Curcumin was dissolved in 
100 μL of DMSO and then 400 μL of corn oil was added; the 
solution was administered by oral gavage once daily, starting 
2 days after leukemic cell injection and continuing to the day 
23. Etoposide (50 mg/kg) was administered intraperitoneally 
once daily for the final 3 days of the experiment. Control 
animals were treated with vehicle only.
Excision of tissues infiltrated by leukemic 
cells and cell isolation
Spleens were excised from rats, weighed, and macerated in a 
Petri dish filled with RPMI-1640 medium. Erythrocytes were 
lysed using red blood cell-lysing buffer containing 0.83% 
ammonium chloride in 0.01 M Tris buffer (pH 7.5).
immunophenotyping and detection of cell 
apoptosis/necrosis
The suspensions of cells isolated from the spleens were stained 
with mouse primary monoclonal anti-RM124 antibody, which 
recognizes the specific epitope that is highly expressed on 
leukemic cells, is rarely found on neutrophils, and is absent 
on normal, nonleukemic blast cells and lymphocytes.24 
Cells were stained with a secondary goat anti-mouse mono-
clonal antibody specific against the μ-chain conjugated to 
R-phycoerythrin. Apoptosis was detected by annexin V 
and 7-amino-actinomycin D (7AAD) staining and analyzed 
with an LSRII flow cytometer (Becton Dickinson). Detailed 
information on the staining procedure can be found in the 
Supplementary materials.
survivin mrna expression in sorted 
BnMl cells, B lymphocytes, and hl-60 
cells
Cells (1×107) were sorted using a MoFlo XDP cell sorter 
(Beckman Coulter, Los Angeles, CA, USA) (Supplementary 
materials). Expression of mRNA was investigated using real-
time polymerase chain reaction (PCR). Gene expression was 
calculated based on the ΔCt method. Detailed information on 
the implementation of reverse transcription–PCR is provided 
in the Supplementary materials.
statistical analysis
One-way analysis of variance (ANOVA) with the Newman–
Keuls post hoc test was used to calculate the statistical 
significance between groups. All data are shown as mean ± 
standard error of the mean.
Results
curcumin enhances the cytotoxic effects 
of etoposide in leukemic cells more 
strongly than in normal cells of myeloid 
origin
Curcumin and etoposide exert cytotoxic activity in HL-60 
cells in a concentration-dependent manner (Figure 1A). The 
investigated polyphenol exerted significant cytotoxic activity 
at a concentration of 20 μM after 24 hours in an HL-60 line. 
Therefore, this concentration of curcumin (20 μM) was used 
in experiments with CD34+ cells and granulocytes. Normal 
proliferating CD34+ cells and mature granulocytes were more 
resistant to the tested compounds (Figure 1). Curcumin con-
centrations of 20 μM did not result in significant  cytotoxicity 
in these normal cells (Figure 1C and D). Etoposide at a con-
centration of 10 μM increased the number of dead CD34+ cells 
by approximately 30% compared to the controls (Figure 1C). 
In contrast, after incubation of HL-60 cells with 10 μM of this 
chemotherapeutic agent, there were three times more dead 
cells than was the case with CD34+ (Figure 1A).
Curcumin significantly intensified the cytotoxic effects 
of etoposide in HL-60 cells (Figure 1A). To determine the 
character of the interaction between the investigated com-
pounds, we analyzed the CI. This analysis showed that most 
cases of combinations of curcumin and etoposide at different 
concentrations exhibited synergism (CI ,0.6, Figure 1B). 
Only the combination of curcumin at a concentration of 
20 μM and etoposide at a concentration of 10 μM showed 
an additive interaction (CI =1.016). Importantly, curcumin 
at a concentration of 20 μM did not significantly modify 
the cytotoxic effects of etoposide in CD34+ cells or mature 
granulocytes (Figure 1C and D). IC
50
 values for etoposide 
and curcumin were 7.29 and 31.17 μM, respectively.
curcumin increases genotoxic and 
apoptotic effects of etoposide in hl-60 cells
To determine whether curcumin can modify the level of 
DSBs induced by etoposide in leukemic and normal cells, 
the intensity of fluorescence of γ-H2AX was determined after 
4-hour incubation with the tested compounds. Other studies 
have shown that etoposide caused intense phosphorylation of 
H2AX after this incubation period.26 Curcumin at a concentra-
tion of 20 μM significantly intensified the phosphorylation of 
H2AX induced by etoposide in HL-60 cells and did not exert 
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curcumin enhances etoposide-induced antileukemic effect
(Figure 2A and B). Intensification of etoposide genotoxicity 
by curcumin in HL-60 cells correlated with the apoptotic 
effect. The percentage of the sub-G1 fraction (subdiploidal 
fraction) increased significantly after incubation of HL-60 
cells with a combination of curcumin at concentrations of 10 
or 20 μM and etoposide (5 μM) in comparison to the use of 
the cytotoxic drug alone (Figure 2C and D). In normal cells, 
there was an observable tendency for an increase in sub-G1 
after treatment with etoposide. A clear but insignificant 
decrease in the level of the subdiploidal fraction was observed 
after cotreatment of normal cells with curcumin 20 μM and 
etoposide compared to the cytotoxic drug alone, especially 
in the case of mature granulocytes (Figure 2C).
curcumin enhances the cytotoxicity of 
etoposide in leukemia cells by increasing 
the oxidative stress
We investigated whether curcumin, as a factor modulating 
ROS-sensitive signaling pathways, has an impact on the cyto-
toxic effect of etoposide in HL-60 cells. Curcumin alone at a 
concentration of 20 μM, exerting a cytotoxic effect in HL-60 
cells, enhanced the oxidative stress in these cells, because its 
action resulted in a significant decrease in the level of reduced 
GSH and an increase in levels of free radicals in comparison 
to the control (Figure 3A–C). A similar effect was exerted in 
HL-60 cells by etoposide at a concentration of 10 μM. The 
combination of curcumin and etoposide significantly enhanced 
the symptoms of oxidative stress, as reflected in a significant 
drop in GSH and increase in free radical levels over that of 
etoposide (Figure 3A–C). On the other hand, preincubation 
with N-acetyl-l-cysteine (NAC) significantly reduced the 
cytotoxic and apoptotic effects of the investigated polyphenol 
and combinations of curcumin (20 μM) and etoposide (10 μM), 
in comparison to the appropriate controls (Figure 3D and E). 
These results indicate that escalating oxidative stress is involved 
in the cytotoxic action of curcumin and in the modification by 
this polyphenol of etoposide cytotoxicity in HL-60 cells.
Curcumin does not significantly modify the 
expression of nuclear nFκB in hl-60 cells
In many studies, the cytotoxic effects of curcumin correlate with 
inhibition of NFκB10,27,28 and, therefore, we investigated whether 
the impact of the synergistic effect of curcumin and etoposide 
leads to a change in the expression of this transcription factor.
×
Figure 1 Influence of curcumin on cytotoxicity induced by etoposide in HL-60 cells, primary CD34+ cells, and granulocytes.
Notes: (A) Cells were incubated with different concentrations of curcumin and/or etoposide for 24 hours, stained using propidium iodide, and analyzed by flow cytometry. 
Percentage of dead hl-60 cells. (B) cooperation pattern of curcumin (7, 10, and 20 μM) and etoposide (3, 5, and 10 μM) combinations in induction of cytotoxicity in 
hl-60 cells. (C) Percentage of dead cD34+ cells after incubation with curcumin and/or etoposide. (D) Percentage of dead granulocytes after incubation with investigated 
compounds. *P,0.05; **P,0.01; ***P,0.001 vs control; ##P,0.01; ###P,0.001 vs etoposide. The experiments were repeated three times. Data are presented as mean ± 
standard error of the mean.
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Figure 2 Influence of curcumin on phosphorylation of H2AX and percentage of sub-G1 fraction induced by etoposide.
Notes: (A) Cells were treated with curcumin and/or etoposide for 4 hours. Intensity of fluorescence of γ-H2AX was measured by flow cytometry. (B) representative contour 
plots of histone γ-h2aX vs Dna staining of hl-60 cells. (C) Percentage of sub-G1 fraction of cell cycle was evaluated by flow cytometry. (D) representative histograms of cell 
cycle distribution and sub-g1 fraction of hl-60 cells. *P,0.05; ***P,0.001 vs control; #P,0.05; ##P,0.01; ###P,0.001 vs etoposide. The experiments were repeated three times. 
Data are presented as mean ± standard error of the mean.
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curcumin enhances etoposide-induced antileukemic effect
We did not find any significant effects of the investigated 
compounds, used separately or in combination, on the nuclear 
level of NFκB (Supplementary figures) or whole-cell level 
of phospho-p65 (data not shown).
curcumin and tetrahydrocurcumin 
content in hl-60 cells
Quantitative analysis using LC/MS showed that the aver-
age content of curcumin is 7.19 μg/mL and that of its major 
Figure 3 Pro-oxidant activity of curcumin and etoposide in hl-60 cells.
Notes: (A) hl-60 cells were incubated with curcumin and/or etoposide for 24 hours. gsh content was detected spectrophotometrically. (B) rOs content in cells was detected 
using cM-h2DCFDA staining and analyzed by flow cytometry. (C) representative histograms of cM-h2DCFDA-derived fluorescence. (D) cells were preincubated for 1 hour 
with NAC, followed by incubation with curcumin and/or etoposide for 24 hours. Cytotoxicity was detected using PI staining and analyzed by flow cytometry. (E) cells were 
preincubated for 1 hour with nac followed by incubation with curcumin and/or etoposide for 24 hours. apoptotic cells were detected using annexin-V/Pi staining and analyzed 
by flow cytometry. *P,0.05; **P,0.01; ***P,0.001 vs appropriate control; #P,0.05; ###P,0.001 vs etoposide. Data are presented as mean ± standard error of the mean.
Abbreviations: aPc, allophycocyanin; cur, curcumin; eto, etoposide; gsh, glutathione; nac, N-acetyl-l-cysteine; cM-h2DcFDa, 5-(and-6)-chloromethyl-2′,7′-
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metabolite tetrahydrocurcumin is 5.25 μg/mL, after 24 hours 
of incubation with 20 μM of the investigated polyphenol 
(Supplementary figures).
curcumin increases the antileukemic 
activity of etoposide in a rat model of 
aMl
To verify whether curcumin can modulate the antileuke-
mic activity of etoposide in vivo, we used a BNML rat 
model of transplantable AML, which closely resembles 
human AML in growth characteristics and chemothera-
peutic susceptibility.24,29 Rats were infused with leukemic 
cells and received curcumin daily from day 2 to day 23 
(Figure 4A). Etoposide was administered for the final 3 days 
(Figure 4A).
Development of leukemia in rats was manifested by a 
decrease in body weight (from 196.6±3.3 to 170.6±7.3 g, 
P,0.05) (Figure 4B), whereas spleen weight was doubled, 
as measured on day 23 after infusion of leukemic cells 
(Figure 4C). Numerous nodules at the surface of the 
spleens additionally confirmed the presence of leukemia 
(Figure 4D).
Etoposide alone effectively reduced the progression of 
the disease, as indicated by the decreased spleen weight 
(Figure 4E). Moreover, flow cytometric analysis (Figure 5A) 
showed that rats treated with etoposide displayed a lower 
proportion of leukemic cells (Figure 5B) and a higher propor-
tion of host B-cells (Figure 5C) in the spleen, when compared 
with their untreated, control counterparts.
At a higher dose of 200 mg/kg, curcumin exerted an 
antileukemic potential comparable to that of etoposide at 
a dose of 50 mg/kg (Figure 4E). Importantly, pretreatment 
with curcumin (200 mg/kg) followed by administration of 
etoposide significantly enhanced the antileukemic effect of 
the drug, further reducing the spleen weight and correct-
ing the proportion of leukemic cells and healthy B-cells 
(Figure 5B and C).
curcumin increases etoposide-induced 
apoptosis of BnMl cells
Given that etoposide is known for its proapoptotic action, we 
checked whether the pretreatment of rats with curcumin can 
modulate etoposide-stimulated apoptosis in leukemic cells. 
As shown in Figure 5D, etoposide administered alone was 
a potent proapoptotic agent, as evidenced by an increased 
proportion of Annexin V-positive leukemic BNML cells 
isolated from the rat spleen.
Curcumin also increased the apoptosis of leukemic cells 
in a dose-dependent manner and, again, the effectiveness of 
the higher dose (200 mg/kg) was similar to that of etopo-
side (Figure 5D). The highest apoptosis rate was found in 
leukemic cells isolated from rats pretreated with curcumin 
(200 mg/kg) and then injected with etoposide (Figure 5D; 
P,0.05 versus etoposide only). This shows that curcumin 
can increase the proapoptotic potential of etoposide in leu-
kemic cells in vivo.
Importantly, this proapoptotic potential seems to be cell-
type selective, as no induction of apoptosis in the nonleuke-
mic B-cells was detected in response to either etoposide alone 
or curcumin (200 mg/kg)/etoposide treatment (Figure 5E). 
Moreover, the low rate of B-cell apoptosis in rat spleens was 
further decreased in the curcumin (200 mg/kg)/etoposide 
group. It appears, however, that the biological meaning 
of these statistically significant differences – decrease in 
B-cell apoptosis in curcumin/etoposide group and some 
increase in animals treated with a lower dose of curcumin 
(100 mg/kg) – is rather questionable, as in no sample did the 
apoptosis rate exceed 0.5% (Figure 5E).
Influence of curcumin on survivin 
expression after etoposide treatment  
of leukemic rats and hl-60 cells
Because leukemic cells are known to overexpress antiapop-
totic proteins, we checked whether curcumin modulates the 
expression of genes involved in these processes. Etoposide 
showed a tendency to induce the expression of antiapop-
totic survivin in leukemic cells, and this effect was partially 
prevented by pretreatment with curcumin (Figure 6A). The 
differences did not, however, reach statistical significance 
(P=0.07, one-way ANOVA). Etoposide and curcumin did 
not affect the expression of survivin in nonleukemic B-cells 
(Figure 6B). Similarly, a combination of curcumin and 
etoposide does not exert significant effect on the expression 
of survivin in comparison to etoposide alone in HL-60 cells. 
Therefore, the level of survivin expression does not play a 
significant role in the antileukemia activity of curcumin/
etoposide (Figure 6C).
Discussion
A major problem in the treatment of AML is its frequent 
recurrence because of the relatively few effective conven-
tional therapies and their high cytogenotoxicity in normal 
cells.30–33 Our in vitro studies show that curcumin has less 
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curcumin enhances etoposide-induced antileukemic effect
Figure 4 leukemia progression and effect of etoposide and/or curcumin on body and spleen weights of BnMl rats.
Notes: (A) scheme of experiment. (B) Body weight of rats before and 23 days after inoculation of leukemic cells. (C) Weight of spleen in rats before and 23 days after 
inoculation of leukemic cells. (D) representative pictures of healthy (day 0) and leukemic (day 23) spleen. (E) effect of curcumin (100 or 200 mg/kg) and/or etoposide (50 mg/
kg) on weight of spleen in rats 23 days after inoculation of leukemic cells. each bar represents mean ± seM. n=8. *P,0.05; ***P,0.001 vs day 0. ###P,0.001 vs etoposide 
alone.
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Figure 5 effect of etoposide and/or curcumin on leukemic cells and healthy B-cells in the spleens of BnMl rats.
Notes: BnMl rats were treated with curcumin (100 or 200 mg/kg) and/or etoposide (50 mg/kg). spleens were excised on day 23 after inoculation of leukemic cells. (A) 
Detection of BNML cells in the rat spleen by flow cytometry. (B) Percentage of leukemic cells in the spleen. (C) Percentage of healthy B-cells in the spleen. (D) apoptosis 
rate in leukemic cells. (E) apoptosis rate in B-cells. Flow cytometry phenotyping and staining with annexin-V/7aaD. each bar represents mean ± seM. *P,0.05; **P,0.01; 
***P,0.001 vs day 0. #P,0.05; ##P,0.01 vs etoposide alone.
Abbreviations: 7aaD, 7-amino-actinomycin D; BnMl, Brown norway myeloid leukemic cells; cD, cluster of differentiation; cont, control; cur, curcumin; eto, etoposide; 
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curcumin enhances etoposide-induced antileukemic effect
myeloid progenitor cells and human granulocytes compared 
with leukemic HL-60 cells.
Cotreatment with curcumin and etoposide exerts a syn-
ergistic cytotoxic effect in HL-60 cells. In another study, 
a similar synergistic effect of curcumin with daunorubicin 
was observed in myeloid leukemic cell lines.34 Intensifying 
the effect of curcumin on the cytotoxic action of etoposide 
has been demonstrated in brain tumor and retinoblastoma 
cell lines.35,36 In the present study, curcumin potentiated 
the cytotoxic effect of etoposide in HL-60 cells through 
intensification of its genotoxicity, which is indicated by 
the significant increase in the amount of γ-H2AX after 
treatment with a combination of curcumin and etoposide, 
accompanied by a corresponding increase in the percent-
age of the sub-G1 fraction in comparison to the cytostatic 
drug alone.
One method to increase the cytogenotoxic effect of 
etoposide by curcumin may be via the ability of this 
polyphenol to intensify oxidative stress in cancer cells. 
We have shown that curcumin significantly potentiated the 
pro-oxidative effect of etoposide in HL-60 cells by increas-
ing the production of free radicals and reducing the level 
of GSH. The pro-oxidative effect of curcumin contributed 
to the escalation of the apoptotic and cytotoxic actions of 
etoposide, as antioxidant NAC significantly reduced the 
cytotoxic effect of the combination of curcumin and etopo-
side in HL-60 cells. The pro-oxidative effect of curcumin 
could also potentiate the DNA damage induced by etoposide 
because it is known that free radicals can directly lead to 
the formation of DSBs.4
Increased levels of free radicals are often observed in 
cancer cells. Pro-oxidants can augment the level of oxida-
tive stress in these cells, and the resulting DNA damage and 
apoptosis, and may lead to cell growth arrest. Our results 
are consistent with those of Sánchez et al,37 who confirmed 
that curcumin induces apoptosis of myeloid leukemia cells 
Figure 6 effect of etoposide and/or curcumin on expression of survivin in leukemic cells and healthy B-cells isolated from the spleens of BnMl rats and in hl-60 cells.
Notes: BnMl rats were treated with curcumin (100 mg/kg or 200 mg/kg) and/or etoposide (50 mg/kg). spleens were excised on day 23 after inoculation of leukemic cells. 
hl-60 cells were incubated with different concentrations of curcumin and/or etoposide for 24 hours. (A) expression of survivin in BnMl cells. (B) expression of survivin 
in B-cells. (C) expression of surviving in hl-60 cells by quantitative rT-Pcr. eF2 served as a housekeeping gene. each bar represents mean ± seM. The analysis of survivin 
expression was repeated three times.
Abbreviations: BnMl, Brown norway myeloid leukemia; cur, curcumin; eF, elongation factor; eto, etoposide; rT-Pcr, reverse transcription polymerase chain reaction; 
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and enhances the cytotoxic activity of arsenic trioxide by 
increasing oxidative stress. Other studies have shown that 
the beta-diketone structure of curcumin is responsible for its 
pro-oxidative effect.38 Analysis using LC/MS revealed that 
curcumin (7.19 μg/mL) quantitatively dominated over the 
main metabolite, tetrahydrocurcumin (THC, 5.25 μg/mL), 
in HL-60 cells. As demonstrated in other studies, THC has 
no pro-oxidative action in cells.39
The present results show that oxidative stress plays a 
greater role in the cytotoxic effect of curcumin than in the case 
of etoposide. Preincubation with NAC significantly reduced 
the cytotoxic effect of curcumin but did not exert such an 
effect on etoposide action. Oxidative stress is thus involved 
in the cytotoxic action of curcumin, and the cytotoxic activity 
of etoposide mainly corresponds to DNA damage.
Curcumin, neither alone nor in combination with etopo-
side, inhibited the nuclear and whole-cell levels of NFκBp65. 
These results are also consistent with the studies of Sánchez 
et al,37 who showed no effect of curcumin on the activation 
and DNA binding of NFκB in AML cells.
It is known that the leukemogenic and myelosuppressive 
effect of etoposide is caused by the cytogenotoxic activity 
in myeloid precursors.19,33 Limiting the cytogenotoxic action 
of etoposide in these cells could allow for an increase in 
the dose of this drug. Our research shows that curcumin 
at a concentration of 20 μM, which enhances the action of 
etoposide in HL-60 cells, leads to an insignificant decrease 
in the number of dead CD34+ cells induced by this cyto-
static drug. One reason for the difference in the effects of 
curcumin on tumor and normal CD34+ cells predisposed to 
leukemogenesis under etoposide action may be endogenous 
differences in the redox state of the cells. It should be added 
that curcumin and etoposide can influence the progenitor 
cells in different ways. Other studies show that stem cells 
are characterized by low levels of the ROS necessary for 
the capacity for self-renewal. While the increase in ROS 
promotes the differentiation of these cells, curcumin and 
etoposide could, theoretically, significantly increase the level 
of ROS in CD34+ cells and affect the ability of these cells to 
effect self-renewal and differentiation.40
It is also known that treatment with etoposide is associ-
ated with neutropenia. In retrospective studies, Buckley et al32 
demonstrated that severe neutropenia is the major risk factor 
for adverse outcomes after induction chemotherapy, increas-
ing the probability of morbidity and mortality in patients with 
AML. The cause of etoposide-induced neutropenia may be 
not only myelosuppression, but also induction of apoptosis/
necrosis of mature neutrophils. Topoisomerase II, an etoposide 
handle, has weak activity in nonproliferating cells. However, 
etoposide can induce the cell death of neutrophils by increas-
ing oxidative stress. In previous studies, it has been demon-
strated that etoposide increases the level of ROS in resting 
neutrophils.41 Therefore, it seems important to investigate the 
effect of curcumin, which is a factor modulating ROS-sensitive 
signaling pathways, in cells treated with etoposide.
We have shown in vitro that curcumin does not potentiate 
the cytogenotoxic etoposide effect in resting granulocytes, 
and that it can even be seen to reduce the tendency toward 
apoptosis exerted by the cytostatic drug, as indicated by 
an insignificant but clear decrease in the percentage of the 
sub-G1 fraction and the level of phosphorylated H2AX after 
treatment with curcumin (20 μM) and etoposide in compari-
son to the results with use of the cytotoxic drug alone.
The in vitro influence of curcumin on the antileukemic 
action of etoposide has been confirmed in further in vivo 
studies performed on a BNML model. This model of trans-
plantable leukemia turned out to be useful in the design 
and translation into clinical practice of new therapeutic 
strategies.24,29 Therefore, we chose it to analyze the anti-
leukemic activity of curcumin. Curcumin administration 
throughout the period of leukemia development resembles 
the situation when the disease recurs after remission, and this 
polyphenol reduces the growth of leukemia.
Our study shows that curcumin, at a higher dose 
(200 mg/kg) and given every second day after injection of 
BNML cells, reduces the progression of leukemia. This 
observation, which confirms the antileukemic potential of 
curcumin, is consistent with earlier studies performed in 
murine WEHI-3 myeloid leukemia models.42 Moreover, we 
demonstrated significant improvement in therapeutic efficacy 
when pretreatment with curcumin was combined with admin-
istration of etoposide. Hence, the BNML cells were sensitive 
to etoposide alone, and administration of the drug during the 
final 3 days of the experiment was sufficient to effect a reduc-
tion of more than twofold in the number of leukemic cells. 
Importantly, pretreatment with curcumin resulted in a further 
enhancement of the antileukemic activity of etoposide.
We also propose a possible mechanism that may underlie 
the observed effect. Our results show that curcumin itself 
triggered apoptosis of leukemic BNML cells in the rat spleen. 
As could be expected, etoposide administration also induced 
apoptosis in leukemic cells. Importantly, the combination of 
etoposide and curcumin treatments increased apoptosis rates 
more than curcumin or etoposide administered separately. 
Therefore, it can be concluded that curcumin enhances the 
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curcumin enhances etoposide-induced antileukemic effect
We have found in vivo that administration of etoposide 
induced expression of survivin in BNML cells growing in the 
rat spleen, an effect clearly attenuated by pretreatment with 
curcumin. However, we could not confirm these observations 
in vitro in HL-60 cells. Therefore, it can be assumed that cur-
cumin does not significantly affect the expression of survivin, 
a downstream target of NF-kB, in BNML cells growing in the rat 
spleen and in HL-60 cells treated with curcumin/etoposide.
Importantly, we did not detect any increase in apoptosis 
rates in nonleukemic splenic B-cells in response to either 
etoposide or the higher dose of curcumin. Unexpectedly, 
a low dose of curcumin (100 mg/kg) significantly increased 
the percentage of apoptotic B-cells. The difference in dose–
response profiles could depend on the quantity of curcumin 
metabolites that may block its action. Furthermore, there 
was a statistically significant decrease in apoptosis in B-cells 
isolated from animals treated with a combination of etopo-
side and curcumin, although the biological significance of 
such a reduction is uncertain due to the very low apoptosis 
rate found in the control B-cells. It should be added that we 
have shown in earlier studies that curcumin enhances the 
antileukemic activity of etoposide in the bone marrow of 
BNML rats, while leading to an increase in the percentage 
of normal granulocyte and erythrocyte precursors compared 
to the group treated with etoposide alone. Thus, curcumin 
may protect normal myeloid precursors against the cyto-
toxic effects of etoposide. Alternatively, due to a significant 
decrease in the percentage of leukemic cells after treatment 
with etoposide and curcumin, the normal cells of the myeloid 
lineage began to dominate.43
Generally, our results indicate that curcumin enhances 
the proapoptotic activity of etoposide, acting selectively in 
leukemic cells. A new element of our research is the dem-
onstration that curcumin in combination with etoposide acts 
synergistically in myeloid leukemia cells. In this activity of 
curcumin, oxidative stress undoubtedly plays an important 
role. Its effect is much stronger in malignant myeloid cells 
than in their normal counterparts. This suggests that curcumin 
could be useful in the design of new anticancer strategies to 
intensify the proapoptotic potential of etoposide in myeloid 
leukemia cells.
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